A Phase 1 Study of SN2310 Injectable Emulsion in Patients with Advanced Solid Tumors.

Welcome to the Sonus Study #SON-2310-06-101 Study Page!

What is Sonus Study #SON-2310-06-101?

This Phase 1 open-label clinical trial, sponsored by Sonus Pharmaceuticals is being conducted to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable Emulsion and to characterize the pharmacokinetics of SN2310 and SN38. The study is expected to enroll up to 61 men and women in the US.

Important Facts about SON-2310-06-101:
  • SON-2310-06-101 will investigate SN2310 Injectable Emulsion in patients with advanced solid malignancies who have failed conventional therapy.
  • SON-2310-06-101 will investigate the maximum tolerated dose of SN2310 Injectable Emulsion.
  • Types of cancers to be allowed in the study include: breast cancer, colorectal cancer, pancreatic cancer, ovarian cancer and lung cancer.
Is SON-2310-06-101 Right For Me?

In order to qualify to participate in SON-2310-06-101 you must first meet the following criteria:

Inclusion Criteria:

  • Confirmed diagnosis of solid tumor with at least 1 unidimensionally measurable lesion as defined by RECIST
  • Progression of disease despite standard therapy and/or for which no other standard therapeutic option exists
  • ANC > 1500 cell/mm3, platelets >100,000/mm3, Hgb >9 g/dl
Exclusion Criteria:
  • Female who is pregnant or lactating
  • History of chronic diarrhea
  • Hypersensitivity to camptothecin containing drugs, including topotecan and irinotecan
Find a Study Center

If you think that you may meet the above criteria and you would like to find out if there is a study center of the US, please see our listing on ClinicalTrials.gov, a service of the US National Institutes of Health.

Click here to go directly to the site.

If you would like more information regarding the above-listed, or information regarding study centers outside the US, please use the following contact information:
View Active Sonus Clinical Trials »


About Clinical Trials


Sources of Clinical Trial Information


The Risks and Benefits of Clinical Trial Participation


Deciding Whether to Participate in a Clinical Trial


Contact Us


Sonus Pharmaceuticals Corporate Website


Home















 
Copyright © 2006 by Sonus Pharmaceuticals, Inc. All rights reserved.